Mecox Cure Med Advances Smoothly in COVID-19 Treatment Development... Concurrent Research on Mass Production Basis

[Asia Economy Reporter Jang Hyowon] MedicoX's subsidiary, Mecox CureMed, announced on the 28th that it has additionally exported the COVID-19 treatment candidate substance ‘M002-A’ and its fractions.

European new drug developer Tube Pharmaceuticals GmbH, which is jointly developing the COVID-19 treatment with Mecox CureMed, requested the candidate substance and fractions.

The substances Mecox CureMed has additionally exported are fractions separated from M002-A, including ZPEF01, ZPEF02, ZPEF03, and ZPEF04. Tube Pharmaceuticals will utilize these fractions in ongoing COVID-19 treatment development experiments to optimize antiviral efficacy and proceed to in vivo experiments to clearly demonstrate the components and mechanism of action.

A Mecox CureMed representative stated, "The additional export of the four M002-A-based fractions is significant because it allows direct confirmation of the treatment effect against COVID-19 through confirmatory in vivo experiments. Since the fractions used in the experiments can also be chemically synthesized, we will conduct foundational research for mass production in preparation for after the successful verification of experimental efficacy."

Earlier, since June, Tube Pharmaceuticals announced that in antiviral efficacy experiments using Mecox CureMed’s ‘M002-A’ conducted at the Virus Research Institute of the University of Padua in Italy, all three concentration samples used in the study, including the lowest concentration drug, showed antiviral effects.

As the joint development project with Tube Pharmaceuticals shows concrete results, Mecox CureMed plans to accelerate the development of the COVID-19 treatment by linking it with projects currently underway with national research institutes.

This content was produced with the assistance of AI translation services.